SG Americas Securities LLC Acquires 4,231 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

SG Americas Securities LLC raised its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 35.0% during the fourth quarter, HoldingsChannel reports. The firm owned 16,307 shares of the biotechnology company’s stock after buying an additional 4,231 shares during the quarter. SG Americas Securities LLC’s holdings in AnaptysBio were worth $216,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Frazier Life Sciences Management L.P. increased its position in shares of AnaptysBio by 2.0% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after purchasing an additional 43,598 shares during the last quarter. Point72 Asset Management L.P. increased its position in AnaptysBio by 202.8% during the third quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock valued at $1,816,000 after acquiring an additional 36,300 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of AnaptysBio by 191.4% in the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company’s stock valued at $1,130,000 after acquiring an additional 22,164 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares during the period.

Insider Buying and Selling

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were purchased at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the transaction, the director now directly owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 33.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on ANAB. UBS Group lifted their target price on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. decreased their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Wells Fargo & Company dropped their target price on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. BTIG Research downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, Wolfe Research assumed coverage on AnaptysBio in a research note on Tuesday. They issued an “outperform” rating and a $25.00 price objective on the stock. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.08.

AnaptysBio Stock Performance

Shares of ANAB stock opened at $14.58 on Friday. AnaptysBio, Inc. has a fifty-two week low of $12.51 and a fifty-two week high of $41.31. The firm has a market capitalization of $443.67 million and a PE ratio of -2.40. The stock’s 50-day simple moving average is $16.69 and its 200-day simple moving average is $26.62.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. The company had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Sell-side analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.